Immune checkpoint inhibitors (ICIs), including anti-programmed cell death-1/programmed death ligand-1 (anti-PD-(L)1) therapies, have improved outcomes in patients with advanced non-small cell lung cancer (NSCLC) and melanoma. However, objective response rates remain limited (40 to 60
Active surveillance (AS) is an increasingly common strategy for managing early prostate cancer. There is however no accepted standard for how AS should be done or what healthcare resources are appropriate. The STRATified CANcer Surveillance programme (STRATCANS) is an evidence based 3-tier risk stratified programme to tailor Active Surveillance (AS). Here we report on its real-world resource utilization following implementation in our unit . Men with a prostate cancer diagnosis and selecting AS were enrolled onto the STRATCANS program. Data on resources used during surveillance was extracted from the clinical records. Per protocol scheduled events (clinic events/MRI/ biopsies), any additional non-scheduled events, and disease progression events were recorded. Total, annualised and per person/year costs were derived using contemporary national tariffs. Comparative resource utilization and costs were modelled against two alternative protocols: A PSA based and MRI intensive protocol. Data from 125 men were included for analysis with a median surveillance time of 3.4 years. Overall 84/125 (67.2
G8 and functional competence may capture different aspects of vulnerability in patients with cancer, but their relationship and associations with quality of life remain unclear. We evaluated the concordance between G8 and functional competence and their associations with health-related quality of life (HRQOL) in patients with urological cancers. We retrospectively analyzed prospectively collected observational data from 1,955 patients with renal cell carcinoma, urothelial carcinoma, or prostate cancer. Functional competence was assessed using the 13-item Tokyo Metropolitan Institute of Gerontology Index of Competence (TMIG-IC), and HRQOL was available for 1,580 patients. Associations between G8 and TMIG-IC were assessed using Spearman’s rank correlation and Cohen’s κ. G8 ≤ 14 and TMIG-IC < 11 were used as abnormal criteria. Poor global quality of life (QOL) was defined as an EORTC QLQ-C30 global QOL score ≤50. G8 and TMIG-IC showed weak correlation (rₛ = 0.361) and low concordance (κ = 0.204). G8 ≤ 14 and TMIG-IC < 11 were independently associated with poor global QOL (odds ratios 2.74 and 2.55, respectively; both p < 0.001). After additional adjustment for the G8 self-rated health item, both associations remained significant. Poor global QOL increased stepwise among patients meeting neither, one, or both criteria (16.9
The aim of this study is to systematically evaluate the efficacy and safety of irinotecan-containing neoadjuvant regimens for locally advanced rectal cancer (LARC). A comprehensive literature search was performed in PubMed, Embase, Web of Science, Cochrane Library to identify studies on irinotecan-containing neoadjuvant regimens for LARC published between January 1, 2000, and January 31, 2026; the search was last executed after this cutoff date, and no eligible study published in 2026 was identified. Study selection was carried out based on predefined inclusion and exclusion criteria, followed by risk-of-bias assessment and data extraction. Meta-analyses were then conducted using Stata 15.0 software. A total of 29 prospective studies involving 1,760 patients were analyzed. For irinotecan administered concurrently with neoadjuvant chemoradiotherapy (nCRT) (24 studies, n = 1,357), the pooled pathological complete response (pCR) rate was 21
